Contraception with Subdermal Implants Releasing Levonorgestrel: A Clinical and Pharmacological Study

References

• Rudel H W., Martinez-Manautou J, Maqueo-Topete M. The role of progestogens in the hormonal control of fertility. Fertil Steril 1965; 16: 158–169
   PubMed Web of Science ®Google Scholar
• Martinez-Manautou J, Cortez V, Giner J, Aznar R, Casasola J, Rudel H W. Low doses of progestogen as an approach to fertility control. Fertil Steril 1966; 17: 49–57
   PubMed Web of Science ®Google Scholar
• Landgren B M., Diczfalusy E. Hormonal effects of the 300 ug norethisterone (NET) mini pill. Contraception 1980; 21: 87–113
   PubMed Web of Science ®Google Scholar
• Fotherby K. The progestogen-only contraceptive Pill. Review article. Br J Fam Plann 1982; 8: 7–10
   Google Scholar
• Folkman J, Long D M. The use of silicone rubber as a carrier for prolonged drug therapy. J Surg Res 1964; 4: 139–142
   PubMed Web of Science ®Google Scholar
• Dziuk P J., Cook B. Passage of steroids through silicone rubber. Endocrinology 1966; 78: 208–211
   PubMed Web of Science ®Google Scholar
• Segal S J., Croxatto H B. Single administration of hormones for long term control of reproductive function. Presentation at the XXIII Meeting of American Fertility Society, Washington, D.C., April, 14–161967
   Google Scholar
• Memorandum from a WHO Meeting. Facts about an implantable contraceptive. Bulletin of the World Health Organization 1985; 63: 485–494
   Google Scholar
• Segal S J. Contraceptive subdermal implants. Advances in Fertility Research, D R. Mishell, Jr. Raven Press, New York 1982; Vol. 1: 117–127
   Google Scholar
• Hill R, Dumas K. The use of dogs for studies of toxicity of contraceptive hormones. Pharmacological models in contraceptive development, M H. Briggs, E Diczfalusy. WHO Symposium, Geneva 1973
   Google Scholar
• Croxatto H, Diaz S, Vera R, Etchart M, Atria P. Fertility control in women with a progestin released in microquantities from subcutaneous capsules. Am J Obstet Gynecol 1969; 105: 1135–1139
   PubMed Web of Science ®Google Scholar
• Coutinho E M., Mattos C E R, Sant'Anna A R S, Adeo-dato Filho J, Silva M C., Tatum H J. Long-term contraception by subcutaneous silastic capsules containing megestrol acetate. Contraception 1970; 2: 313–317
   Google Scholar
• Croxatto H B., Diaz S, Atria P, Cheviakoff S, Rosatti S, Oddo H. Contraceptive action of megestrol acetate implants in women. Contraception 1971; 4: 155–159
   Google Scholar
• Tejuja S. Use of subcutaneous Silastic capsules for long-term steroid contraception. Am J Obstet Gynecol 1970; 107: 954–958
   Google Scholar
• Bergsjo P, Langenen H, Aas J. Tubal pregnancies in women using progestin-only contraception. Acta Obstet Gynecol Scand 1974; 53: 377–381
   Web of Science ®Google Scholar
• Diaz S, Pavez M, Robertson D N., Croxatto H B. A three year clinical trial with levonorgestrel silastic implants. Contraception 1979; 19: 557–573
   PubMed Web of Science ®Google Scholar
• Heinonen O P., Slone D, Monson R R., Hook E B., Shapiro S. Cardiovascular birth defects and antenatal exposure to female sex hormones. N Engl J Med 1977; 296: 67–70
   PubMed Web of Science ®Google Scholar
• Croxatto H B., Diaz S, Quinteras E, Simoneti L, Kaplan E, Rencoret R, Leixland P, Martinez C. Clinical assessment of subdermal implants of megestrol acetate, dnorgestrel, and norethindrone as a long-term contraceptive in women. Contraception 1975; 12: 615–619
   Google Scholar
• Coutinho E. Clinical experience with implant contraception. Contraception 1978; 18: 411–427
   PubMedGoogle Scholar
• Population Council, the International Committee for Contraception Research. Contraception with long acting subdermal implants: I. An effective and acceptable modality in international clinical trials. Contraception 1978; 18: 315–333
   Google Scholar
• Population Council, the International Committee for Contraception Research. Contraception with long acting subdermal implants: II. measured and percieved effects in international clinical trials. Contraception 1978; 18: 335–353
   Google Scholar
• Weiner E, Johansson E D B. Plasma levels of d-Nor-gestrel, estradiol and progesterone during treatment with silastic implants containing d-Norgestrel. Contraception 1976; 14: 81–92
   PubMed Web of Science ®Google Scholar
• Sivin I. Findings in Phase III Studies of NORPLANTR implants. Long-Acting Contraceptive Delivery Systems, G I. Zatuchni, A Goldsmith, J D. Shelton, J J. Sciarra. Harper and Row, Philadelphia 1983; 488–500
   Google Scholar
• Robertson D N. Implantable Levonorgestrel Rod Systems: In vivo Release Rates and Clinical Effects. Long-Acting Contraceptive Delivery Systems, G I. Zatuchni, A Goldsmith, J D. Shelton, J J. Sciarra. Harper and Row, Philadelphia 1983; 133–144
   Google Scholar
• Langer R S. Polymers and Drug Delivery Systems. Long-Acting Contraceptive Delivery Systems, G I. Zatuchni, A Goldsmith, J D. Shelton, J J. Sciarra. Harper and Row, Philadelphia 1983; 23–32
   Google Scholar
• Robertson D N., Sivin I, Nash H, Braun J, Dinh J. Release rates of levonorgestrel from Silastic capsules, homogenous rods and covered rods in humans. Contraception 1983; 27: 483–495
   PubMed Web of Science ®Google Scholar
• Croxatto H B., Diaz S, Miranda P, Elamsson K, Johansson E D B. Plasma levels of levonorgestrel in women during long-term use of NORPLANT. Contraception 1980; 22: 583–596
   Google Scholar
• Jain A, Sivin I. Life-Table Analysis of IUDs. Problems and recommendations. Studies in Family Planning 1977; 8: 2
   Google Scholar
• Azen S P., Roy S, Pike M C., Casagrande J, Mishell D R. Jr. A new procedure for the statistical evaluation of intrauterine contraception. Am J Obstet Gynecol 1977; 128: 329–335
   PubMed Web of Science ®Google Scholar
• Farley T M M. Life-table methods for contraceptive research. Statistics in Medicine 1986; 5: 475–489
   PubMed Web of Science ®Google Scholar
• Abraham G, Swerdloff R, Tulchinsky D, Odell W D. Radioimmunoassay of Plasma Progesterone. J Clin Endocrinol Metab 1971; 32: 619–624
   PubMed Web of Science ®Google Scholar
• Rosner W. A simplified method for the quantitative determination of tetosterone-oestradiol binding globulin activity in human plasma. J Clin Endocrinol Metab 1972; 34: 983–988
   PubMed Web of Science ®Google Scholar
• Odlind V, Elamsson K, Englund D, Victor A, Johansson E D B. Effects of estradiol on sex hormone binding globulin. Acta Endocrinol 1982; 101: 248–253
   PubMedGoogle Scholar
• Wide L. Use of particulate immunosorbents in radioimmunoassay. Immunochemical techniques, H Van Vunakis, J J. Langone. Academic Press, New York 1981; vol B: 203–224
   Google Scholar
• Wide L, Dahlberg P A. Quality requirements of basal s-TSH assays in predicting a s-TSH response to TRH. Scand J Clin Lab Invest 1980; 40(Suppl 155)101–110
   Web of Science ®Google Scholar
• Robinson P A., Langley M S., Hammond G L. A solid-phase radioimmunoassay for human corticosteroid binding globulin. J Endocr 1985; 104: 259–267
   Google Scholar
• Edqvist L E., Johansson E D B. Radioimmunoassay of oestrone and oestradiol in human and bovine peripheral plasma. Acta Endocrinol (Copenh) 1972; 71: 716–730
   PubMedGoogle Scholar
• Lindberg B S., Lindberg P, Martinsson K, Johansson E D B. Radioimmunological methods for the estimation of oestrone, oestradiol 17-beta and oestriol in pregnancy plasma. Acta Obstet Gynecol Scand 1974, Suppl 32: 5–19
   Google Scholar
• Thorneycroft I H., Stone S C. Radioimmunoassay of serum progesterone in women receiving oral contraceptive steroids. Contraception 1972; 5: 129–146
   PubMed Web of Science ®Google Scholar
• Bosu W T K, Edqvist L E., Lindberg P, Martinsson K, Johansson E D B. The effects of various doses of lynestrenol on the plasma levels of oestrogens and progesterone during the menstrual cycle in the rhesus monkey. Contraception 1976; 13: 677–684
   PubMed Web of Science ®Google Scholar
• Wide L, Nillius S J., Gemzell C A., Roos P. Radioimmunosorbent assay of follicle-stimulating hormone and luteinizing hormone in serum and urine from men and women. Acta Endocrinol Suppl 1973; 174: 7–58
   Google Scholar
• Diaz S, Pavez M, Miranda P, Herreros C, Johansson E D B, Croxatto H B. Bleeding patterns, outcome of pregnancies, and levonorgestrel plasma levels associated with method failure in NORPLANTR implant users. Contraception 1986; 33: 347–356
   PubMed Web of Science ®Google Scholar
• Victor A, Weiner E, Johansson E D B. Sex hormone binding globulin: the carrier protein for d-norgestrel. J Clin Endocrinol Metab 1976; 43: 244–247
   Web of Science ®Google Scholar
• Victor A, Johansson E D B. Effects of d-norgestrel induced decreases in sex hormone binding globulin capacity on the d-norgestrel levels in plasma. Contraception 1977; 16: 115–123
   Google Scholar
• Toddyvalla V, Johannison E, Landgren B M., Cekan S Z., Diczfalusy E. Pharmacodynamic effects of ethinyl-estradiol in women using vaginal devices releasing small doses of levonorgestrel at a constant rate. Contraception 1983; 28: 21–39
   Google Scholar
• Haukamaa M. Contraception by NORPLANTR sub-dermal capsules is not reliable in epileptic patients on anticonvulsant treatment. Contraception 1986; 33: 559–565
   Google Scholar
• Beastall G H., Cowan R A., Gray J M B, Fogelman I. Hormone binding globulins and anticonvulsant therapy. Scott Med J 1985; 30: 101–105
   PubMed Web of Science ®Google Scholar
• Dowsett M, Attree S L., Virdee S S., Jeffcoate S L. Oestrogen related changes in sex hormone binding globulin levels during normal and gonadotrophin-stimulated menstrual cycles. Clin Endocrinol (Oxf) 1985; 23: 303–12
   PubMed Web of Science ®Google Scholar
• Apter D, Bolton N J., Hammond G L., Vihko R. Serum sex hormone-binding globulin during puberty in girls and in different types of adolescent menstrual cycles. Acta Endocrinol 1984; 107: 413–419
   PubMedGoogle Scholar
• Carlstrom K, Odlind V. Androgen metabolism in the perimenarcheal period. Gynecology and Obstetrics, H Ludwig, K Thomsen. Springer-Verlag, Berlin 1986; 798–802
   Google Scholar
• Cunningham S K., Loughlin T, Culliton M, McKenna T J. The relationship between sex steroids and sex-hormone-binding globulin in plasma in physiological and pathological conditions. Ann Clin Biochem 1985; 22: 489–497
   PubMed Web of Science ®Google Scholar
• Wakonig P, Rothlauer W, Koltringer P, Lind P, Eber O. Diagnosis of peripheral thyroid hormone effect using sex-hormone-bindning globulin (SHBG) and systolic time intervals (STI). Acta Med Austriaca 1986; 13: 5–8, (Ger).
   Google Scholar
• Hammond G L., Langley M S., Robinson P A., Nummi S, Lund L. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel. Fertil Steril 1984; 42: 44–51
   PubMed Web of Science ®Google Scholar
• Population Council, The International Committee for Contraception Research. Contraception with long-acting subdermal implants. A five-year clinical trial with Silastic covered rod implants containing levonorgestrel. Contraception 1985; 31: 351–359
   Google Scholar
• Fraser I S. Menstrual changes associated with progestogenonly contraception. Acta Obstet Gynecol Scand Suppl 1986; 134: 21–27, 1986
   Google Scholar
• Hourihan H M., Sheppard B L., Bonnar J. A morphometric study of the effect of oral norethisterone or levonorgestrel on endometrial blood vessels. Contraception 1986; 34: 603–612
   PubMed Web of Science ®Google Scholar
• Workshop by the Swedish Society for Obstetrics and Gynaecology. Genital infections with Chlamydia Trachomatis, B Linkoping, Swe 1986, Report from Working groups of the Swedish Society for Obsterics and Gynaecology (Ed Kjessler ) No:11
   Google Scholar
• Vermeulen A, Verdonck L, van der Straeten M, Orie N. Capacity of the testosterone-binding globulin capacity in human plasma and influence of specific binding of testosterone on its metabolic clearence rate. J Clin Endocrinol Metab 1969; 29: 1470–1480
   Web of Science ®Google Scholar
• Lobl T J. Androgen transport proteins: physical properties, hormonal regulation, and possible mechanism of T, CBG and ABP Action. Arch Androl 1981; 7: 131–151
   Google Scholar
• Anderson D C. Sex-hormone binding globulin. Clin Endocrinol 1974; 3: 69–96
   PubMed Web of Science ®Google Scholar
• Laurell C B., Rannevik G. A comparison of plasma protein changes induced by danazol, pregnancy and oest-rogens. J Clin Endocrinol Metab 1979; 49: 719–725
   PubMed Web of Science ®Google Scholar
• Rosenfield R L. Studies of the relation of plasma androgen levels to androgen action in women. J Steroid Biochem. 1975; 6: 695–702
   PubMedGoogle Scholar
• Lucky A, McGuire J, Rosenfield R, Lycky P, Rich B. Plasma androgens in women with acne vulgaris. J Invest Dermatol 1983; 81: 70–74
   PubMed Web of Science ®Google Scholar
• Pochi P E. Endocrinology of acne. (Editorial). J Invest Dermatol 1983; 81: 1
   Google Scholar
• Rudorff K H., Herrmann J, Dietrich T, Kruskemper H L. Effect of estrogen upon thyroid metabolism. Med Klin 1978; 73: 1109–1113
   Google Scholar
• Ruokonen A, Kaar K. Effects of desogestrel, levonorgestrel and lynestrenol on serum sex hormone binding globulin, Cortisol binding globulin, ceruloplasmin and HDL-cholesterol. Europ J Obstet Gynec Reprod Biol 1985; 20: 13–18
   Google Scholar
• Brien T G. Human corticosteroid binding globulin, review article. Clin Endocrinol 1981; 14: 193–212
   PubMedGoogle Scholar
• Bayad M A., Ibrahim I, Fayad M M., Hassanein A A., Hafez E S E, Abdalla M I. Serum Cortisol in women users of subdermal levonorgestrel implants. Contraceptive Delivery Systems 1983; 4: 133–135
   Google Scholar
• Croxatto H B., Diaz S, Pavez M. Clinical Chemistry in women treated with progestogen implants. Contraception 1978; 18: 441–450
   Google Scholar
• Diaz S, Croxatto H B., Pavez M. Clinical chemistry in women treated with six levonorgestrel covered rods or with a copper IUD. Contraception 1985; 31: 321–331
   Google Scholar
• Croxatto H B., Diaz S, Robertson D N., Pavez M. Clinical chemistry in women treated with levonorgestrel implants (Norplant) or a TCu 200 IUD. Contraception 1983; 27: 281–288
   PubMed Web of Science ®Google Scholar
• Weitzman E, Fukushima D, Nogeire C, Roffwarg H, Gallagher T F., Hellman D. Twenty-four hour pattern of the episodic secretion of Cortisol in normal subjects. J Clin Endocrinol Metab 1971; 33: 14–22
   PubMed Web of Science ®Google Scholar
• Follenius M, Brandenberger G. Plasma free Cortisol during secretory episodes. J Clin Endocrinol Metab 1986; 62: 609–612
   Google Scholar
• Moore D E., Roy S, Stanczyk F Z., Mishell D R., Jr. Bleeding and Serum d-Norgestrel, Estradiol, and Progesterone Patterns in Women using d-Norgestrel Subdermal Polysiloxane Capsules for Contraception. Contraception 1978; 17: 315–328
   PubMed Web of Science ®Google Scholar
• Croxatto H B., Diaz S, Pavez M, Miranda P, Brandeis A. Plasma progesterone levels during Iongterm treatment with levonorgestrel Silastic implants. Acta Endocrinol 1982; 101: 307–311
   PubMedGoogle Scholar
• Diaz S, Pavez M, Robertson D N., Sivin I, Croxatto H B. A five-year clinical trial of levonorgestrel silastic implants (NORPLANTR). Contraception 1982; 25: 447–456
   PubMed Web of Science ®Google Scholar
• Croxatto H D., Diaz S, Croxatto H B. Adnexal complications in women under treatment with progestogen implants. Contraception 1975; 12: 629–637
   Google Scholar
• Judd S J. The neuroendocrinology of reproduction. Clinical Reproductive Endocrinology, R P. Shearman. Churchill and Livingstone, Edinburgh 1985; 1–37
   Google Scholar
• Johansson E D B. Depression of the progesterone levels in women treated with synthetic gestagens after ovulation. Acta Endocrinol 1971; 68: 779–792
   Google Scholar
• Brache V, Faundes A, Johansson E D B, Alvarez F. Anovulation, inadequate luteal phase and poor sperm penetration in cervical mucus during prologed use of NORPLANT1* implants. Contraception 1985; 31: 261–273
   PubMed Web of Science ®Google Scholar